Patients with a calculated PRA higher than 0% per solid phase and / or anti-HLA class I and / or class II antibodies detectable by single antigen test (Luminex®).
Positive result of Cross Match.
Patients who receive a graft from a cadaver donor.
Identical HLA patients
Patients who have undergone a previous solid organ transplant (including kidney transplant) or who are going to receive another solid organ transplant concomitantly.
Glomerular primary focal and segmental sclerosis
Atypical hemolytic uremic syndrome (aHUS) / thrombotic thrombocytopenic purpura syndrome.
Patients with chronic infection with Hepatitis B virus (HBV) and / or active infection with Hepatitis C virus (positive PCR result) at the time of transplant.
Patients with infection with the known Human Immunodeficiency Virus (HIV).
Patients with active systemic infection that requires the continued administration of antibiotics.
Patients with any neoplasm except localized skin cancer and who is receiving adequate treatment.
Patients with severe anemia (hemoglobin <6g / dl), leukopenia (WBC <2500 / mm3) and / or thrombocytopenia (platelets <80,000 / mm3).
Patients who are hemodynamically unstable even if they have hemoglobin levels> 6g / dL.
Patients with intestinal pathology or severe diarrhea that may decrease absorption according to medical criteria.
Patients with known hypersensitivity to any of the drugs used in this study.
Patients who have received any investigational drug in the 30 days prior to their inclusion in this study.
Potentially fertile women who do not agree to use reliable contraceptive measures during the trial, who are pregnant, breastfeeding or who present a positive pregnancy test at the time of their inclusion in the study.
Patients who are legally detained in an official institution.

NCT03465397_exc_T1
Measurement
calculated PRA
NCT03465397_exc_T2
Value
higher than 0% per solid phase
NCT03465397_exc_T3
Procedure
single antigen test
NCT03465397_exc_T4
Value
anti-HLA class I
NCT03465397_exc_T5
Value
anti-HLA class II
NCT03465397_exc_T6
Scope
anti-HLA class I and / or class I
NCT03465397_exc_T7
Procedure
Luminex
NCT03465397_exc_T8
Procedure
graft from a cadaver donor
NCT03465397_exc_T9
Condition
Identical HLA
NCT03465397_exc_T10
Procedure
Cross Match
NCT03465397_exc_T11
Value
Positive
NCT03465397_exc_T12
Procedure
solid organ transplant
NCT03465397_exc_T13
Temporal
previous
NCT03465397_exc_T14
Procedure
kidney transplant
NCT03465397_exc_T15
Qualifier
another
NCT03465397_exc_T16
Procedure
solid organ transplant
NCT03465397_exc_T17
Temporal
concomitantly
NCT03465397_exc_T18
Condition
rular primary focal and osis
Atyp
NCT03465397_exc_T19
Condition
rular prim ntal sclerosis
Atyp
NCT03465397_exc_T20
Condition
Atypical hemolytic uremic syndrome (aHUS)
NCT03465397_exc_T21
Condition
thrombotic thrombocytopenic purpura syndrome
NCT03465397_exc_T22
Condition
Hepatitis B virus (HBV)
NCT03465397_exc_T23
Condition
Hepatitis C virus
NCT03465397_exc_T24
Procedure
PCR result
NCT03465397_exc_T25
Value
positive
NCT03465397_exc_T26
Qualifier
chronic
NCT03465397_exc_T27
Qualifier
active
NCT03465397_exc_T28
Scope
positive PCR result
NCT03465397_exc_T29
Scope
chronic infection with Hepatitis B virus (HBV) and / or active infection with Hepatitis C virus
NCT03465397_exc_T30
Temporal
at the time of transplant
NCT03465397_exc_T31
Condition
Human Immunodeficiency Virus (HIV)
NCT03465397_exc_T32
Condition
systemic infection
NCT03465397_exc_T33
Qualifier
active
NCT03465397_exc_T34
Drug
antibiotics
NCT03465397_exc_T35
Multiplier
continued administration
NCT03465397_exc_T36
Condition
neoplasm
NCT03465397_exc_T37
Negation
except
NCT03465397_exc_T38
Condition
localized skin cancer
NCT03465397_exc_T39
Qualifier
severe
NCT03465397_exc_T40
Condition
anemia
NCT03465397_exc_T41
Measurement
hemoglobin
NCT03465397_exc_T42
Value
<6g / dl
NCT03465397_exc_T43
Condition
leukopenia
NCT03465397_exc_T44
Measurement
WBC
NCT03465397_exc_T45
Value
<2500 / mm3
NCT03465397_exc_T46
Scope
hemoglobin <6g / dl
NCT03465397_exc_T47
Scope
WBC <2500 / mm3
NCT03465397_exc_T48
Scope
severe anemia
NCT03465397_exc_T49
Condition
thrombocytopenia
NCT03465397_exc_T50
Measurement
platelets
NCT03465397_exc_T51
Value
<80,000 / mm3
NCT03465397_exc_T52
Scope
platelets <80,000 / mm3
NCT03465397_exc_T53
Condition
hemodynamically unstable
NCT03465397_exc_T54
Measurement
hemoglobin levels
NCT03465397_exc_T55
Value
> 6g / dL
NCT03465397_exc_T56
Condition
intestinal pathology
NCT03465397_exc_T57
Condition
severe diarrhea
NCT03465397_exc_T58
Observation
may decrease absorption
NCT03465397_exc_T59
Scope
intestinal pathology or severe diarrhea
NCT03465397_exc_T60
Condition
hypersensitivity
NCT03465397_exc_T61
Drug
drugs used in this study
NCT03465397_exc_T64
Observation
legally detained
NCT03465397_exc_T65
Visit
official institution